Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data
Showed Superior Diabetes Risk-Benefit From Higher Ozempic Dose
Reductions in blood glucose seen in the SUSTAIN FORTE study using a higher dose of Ozempic may help type 2 diabetes patients further improve their diabetes control, with comparable tolerability to currently approved Ozempic 1.0 mg.
You may also be interested in...
In a series of articles, Scrip takes a look at some of the key novel products expected to reach the market in 2022 in a cross-section of therapy areas. Here, with input from Biomedtracker, are nine new products for endocrine and metabolic disorders that could make their debuts next year.
The dual GLP-1/GIP agonist outpaced Novo's blockbuster GLP-1 analogue at all three doses, including the important low dose, on A1C reduction and weight reduction in patients with type 2 diabetes.
Zealand Pharma’s recently installed CEO says it is building US operations to prepare for four potential approvals there in 2020, with commercial launches starting in 2021, its first ever.